TRELEGY ELLIPTA
ICSLAMALABA DPI
Fluticasone furoate / Umeclidinium / Vilanterol · GlaxoSmithKline
Active Medication & Mechanism
- Fluticasone furoate ICS100 mcg or 200 mcg per blister (strip 1)
Synthetic corticosteroid with enhanced glucocorticoid receptor affinity. Provides potent anti-inflammatory activity with once-daily dosing.
- Umeclidinium bromide LAMA62.5 mcg per blister (strip 2)
Long-acting muscarinic antagonist. Blocks M3 receptors on airway smooth muscle, preventing cholinergic bronchoconstriction.
- Vilanterol trifenatate LABA25 mcg per blister (strip 2)
Long-acting beta2-adrenergic agonist. Provides sustained bronchodilation (≥24 hours) via beta2-receptor stimulation.
FDA-Approved Dosing — Strength × Indication
Strength Regimen AsthmaCOPD
100/62.5/25 mcg
1 inhalation once daily → 100/62.5/25 mcg
FDA Approved
Maintenance treatment of asthma in adults not adequately controlled with ICS/LABA.
FDA Approved
Maintenance treatment of patients with COPD. First FDA-approved once-daily single-inhaler triple therapy. Reduces exacerbations and improves lung function.
200/62.5/25 mcg
1 inhalation once daily → 200/62.5/25 mcg
FDA Approved
For patients requiring higher ICS dose. Not adequately controlled on 100/62.5/25.
Not Approved
The 200/62.5/25 strength is NOT indicated for COPD. Only 100/62.5/25 is approved for COPD.
All regimens shown apply to adults (≥18 years) unless otherwise noted · verify against current labelling
100/62.5/25 mcg 1 inhalation once daily → 100/62.5/25 mcg
Asthma FDA Approved
Maintenance treatment of asthma in adults not adequately controlled with ICS/LABA.
COPD FDA Approved
Maintenance treatment of patients with COPD. First FDA-approved once-daily single-inhaler triple therapy. Reduces exacerbations and improves lung function.
200/62.5/25 mcg 1 inhalation once daily → 200/62.5/25 mcg
Asthma FDA Approved
For patients requiring higher ICS dose. Not adequately controlled on 100/62.5/25.
COPD Not Approved
The 200/62.5/25 strength is NOT indicated for COPD. Only 100/62.5/25 is approved for COPD.
All regimens shown apply to adults (≥18 years) unless otherwise noted · verify against current labelling
Not a rescue inhaler. Not for acute bronchospasm. Use a SABA.
Related Inhalers
Other ICS + LABA + LAMA inhalers